Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- 19 January 2026
- journal article
- review article
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (4) , 403-409
Abstract
Background: The optimal timing of initiating direct oral anticoagulants (DOACs) after ischemic stroke in patients with atrial fibrillation (AF) remains uncertain. Early initiation may reduce recurrent stroke risk but raise concerns about hemorrhagic complications. This study aimed to evaluate the efficacy and safety of early versus later anticoagulation after ischemic stroke in AF. Methods: We systematically searched PubMed, EMBASE, CENTRAL, and Scopus from inception to May 22, 2025, for randomized controlled trials (RCTs) comparing early (≤4 days) versus later (5-14 days) DOAC initiation post-stroke in AF. Primary outcomes were recurrent ischemic stroke, symptomatic intracerebral hemorrhage (sICH), and all-cause mortality. Data were pooled using MetaXL (version 5.3) with a random-effects model. Heterogeneity was assessed using the Chi-square test and I 2 statistic. Results: Five RCTs (n = 6810) were included. Early anticoagulation showed a non-significant reduction in recurrent ischemic stroke (OR 0.80, 95% CI: 0.59-1.09; I 2 = 1%) and no significant difference in sICH (OR 0.92, 95% CI: 0.45-1.85; I 2 = 0%) or all-cause mortality (OR 0.94, 95% CI: 0.78-1.14; I 2 = 0%). Across all outcomes, heterogeneity was low and findings were consistent. Conclusion: Early initiation of DOACs after ischemic stroke in AF appears safe and may modestly reduce stroke recurrence without increasing hemorrhagic or mortality risk. These findings support individualized decision-making and suggest that early anticoagulation is a reasonable strategy in appropriately selected patients.Keywords
This publication has 15 references indexed in Scilit:
- Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial FibrillationJAMA Neurology, 2025
- Department of ErrorThe Lancet, 2025
- Secondary stroke prevention in people with atrial fibrillation: treatments and trialsThe Lancet Neurology, 2024
- Direct Oral Anticoagulants: An Overview of Indications, Pharmacokinetics, Comorbidities, and Perioperative ManagementCardiology in Review, 2023
- Early versus Later Anticoagulation for Stroke with Atrial FibrillationNew England Journal of Medicine, 2023
- Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority StudyCirculation, 2022
- Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and SexCirculation, 2022
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Evolving Treatments for Arterial and Venous ThrombosisCirculation Research, 2016